Although the KO of METTL3 or the application of METTL3 inhibitors in tumour cells has been shown to augment the efficacy of ICB therapy, there is a lack of attention to the impact of METTL3 on T cells within the tumour microenvironment. The gene discussed is METTL3; the disease is neoplasm.